106 related articles for article (PubMed ID: 26342276)
1. Daily intake of β-cryptoxanthin prevents bone loss by preferential disturbance of osteoclastic activation in ovariectomized mice.
Ozaki K; Okamoto M; Fukasawa K; Iezaki T; Onishi Y; Yoneda Y; Sugiura M; Hinoi E
J Pharmacol Sci; 2015 Sep; 129(1):72-7. PubMed ID: 26342276
[TBL] [Abstract][Full Text] [Related]
2. The natural polyamines spermidine and spermine prevent bone loss through preferential disruption of osteoclastic activation in ovariectomized mice.
Yamamoto T; Hinoi E; Fujita H; Iezaki T; Takahata Y; Takamori M; Yoneda Y
Br J Pharmacol; 2012 Jun; 166(3):1084-96. PubMed ID: 22250848
[TBL] [Abstract][Full Text] [Related]
3. Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice.
Alles N; Soysa NS; Hayashi J; Khan M; Shimoda A; Shimokawa H; Ritzeler O; Akiyoshi K; Aoki K; Ohya K
Endocrinology; 2010 Oct; 151(10):4626-34. PubMed ID: 20810563
[TBL] [Abstract][Full Text] [Related]
4. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
5. Role of carotenoid β-cryptoxanthin in bone homeostasis.
Yamaguchi M
J Biomed Sci; 2012 Apr; 19(1):36. PubMed ID: 22471523
[TBL] [Abstract][Full Text] [Related]
6. Daily oral supplementation of Hochu-Ekki-To prevents osteoclastic activation and bone loss in ovariectomized mice.
Ochiai S; Tokumura K; Park G; Ozaki K; Horie T; Yamada T; Iwahashi S; Ohta K; Fusawa H; Okayama Y; Kaneda K; Iezaki T; Hinoi E
J Pharmacol Sci; 2021 Jan; 145(1):1-5. PubMed ID: 33357767
[TBL] [Abstract][Full Text] [Related]
7. Eriodicyol inhibits osteoclast differentiation and ovariectomy-induced bone loss in vivo.
Lee J; Noh AL; Zheng T; Kang JH; Yim M
Exp Cell Res; 2015 Dec; 339(2):380-8. PubMed ID: 26450448
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
Uchiyama S; Yamaguchi M
Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
[TBL] [Abstract][Full Text] [Related]
9. Quinoxaline derivative of oleanolic acid inhibits osteoclastic bone resorption and prevents ovariectomy-induced bone loss.
Zhao Y; Huai Y; Jin J; Geng M; Li JX
Menopause; 2011 Jun; 18(6):690-7. PubMed ID: 21228726
[TBL] [Abstract][Full Text] [Related]
10. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
12. Oral administration of beta-cryptoxanthin prevents bone loss in ovariectomized rats.
Uchiyama S; Yamaguchi M
Int J Mol Med; 2006 Jan; 17(1):15-20. PubMed ID: 16328006
[TBL] [Abstract][Full Text] [Related]
13. Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia.
Hinoi E; Ochi H; Takarada T; Nakatani E; Iezaki T; Nakajima H; Fujita H; Takahata Y; Hidano S; Kobayashi T; Takeda S; Yoneda Y
J Bone Miner Res; 2012 Apr; 27(4):938-49. PubMed ID: 22190281
[TBL] [Abstract][Full Text] [Related]
14. Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
Narayana Murthy PS; Sengupta S; Sharma S; Singh MM
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):117-28. PubMed ID: 16797179
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors of IkappaB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo.
Idris AI; Krishnan M; Simic P; Landao-Bassonga E; Mollat P; Vukicevic S; Ralston SH
FASEB J; 2010 Nov; 24(11):4545-55. PubMed ID: 20647545
[TBL] [Abstract][Full Text] [Related]
16. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.
Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
Drug Des Devel Ther; 2015; 9():3755-66. PubMed ID: 26229438
[TBL] [Abstract][Full Text] [Related]
17. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
Idris AI; Landao-Bassonga E; Ralston SH
Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
[TBL] [Abstract][Full Text] [Related]
18. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.
Most W; Schot L; Ederveen A; van der Wee-Pals L; Papapoulos S; Löwik C
J Bone Miner Res; 1995 Oct; 10(10):1523-30. PubMed ID: 8686508
[TBL] [Abstract][Full Text] [Related]
19. Honokiol stimulates osteoblastogenesis by suppressing NF-κB activation.
Yamaguchi M; Arbiser JL; Weitzmann MN
Int J Mol Med; 2011 Dec; 28(6):1049-53. PubMed ID: 21887456
[TBL] [Abstract][Full Text] [Related]
20. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
